This bill prohibits the use of federal taxpayer funds for gender transition procedures and bars federal health plans and ACA premium credits from covering such care.
Doug LaMalfa
Representative
CA-1
The End Taxpayer Funding of Gender Experimentation Act of 2025 prohibits the use of any federal funds for gender transition procedures, including those provided through federal health plans or facilities. This ban also extends to the Affordable Care Act, preventing individuals from using federal premium tax credits or cost-sharing reductions to cover plans that include such procedures. The legislation broadly defines gender transition procedures while excluding care for certain disorders of sex development and life-threatening emergencies.
The “End Taxpayer Funding of Gender Experimentation Act of 2025” is straightforward: it aims to completely cut off federal dollars from paying for gender transition procedures. This isn't just about direct government spending; the bill reaches into federal employee health plans, care provided in federal facilities, and critically, the Affordable Care Act (ACA) marketplaces. If this passes, it fundamentally changes who pays for what, and who can access this type of care if they rely on federal programs.
Title I of the bill is the big hammer, declaring that no federal money—from appropriations to trust funds—can be spent on what it defines as "gender transition procedures." This ban applies broadly: federal health plans can’t cover it, and health workers employed by the federal government can’t perform it in federal facilities. For a veteran relying on the VA system or a federal employee using their government-sponsored insurance, this means that coverage for these specific treatments vanishes.
The bill defines “Gender Transition Procedure” very specifically, including things like puberty-blocking drugs (GnRH agonists), high-dose hormone therapy, and various surgeries like hysterectomy, phalloplasty, and vaginoplasty. The only exceptions are treatment for complications from a prior procedure, care for people born with a verifiable disorder of sex development (DSD), or in cases of imminent life-threatening danger. If you’re a federal worker or a veteran, you would have to seek and pay for this care entirely outside the federal system, which is a major logistical and financial hurdle.
Title II targets the ACA, which is where millions of people get their health coverage. The bill states that if a health plan purchased on the marketplace covers gender transition procedures, the consumer cannot use the federal premium tax credit (the subsidy that lowers their monthly payment) to buy that plan. This is a huge deal for people who rely on those credits to afford insurance.
Imagine you’re a freelancer in the gig economy. You buy insurance on the ACA exchange and use a tax credit to make it affordable. If you need this specific coverage, you would have to choose a plan that includes it, but you would lose the subsidy, potentially making the monthly premium thousands of dollars more expensive. The same rule applies to the small employer health insurance credit: if a small business wants to claim that tax break, their employee health plan cannot cover these procedures. While the bill allows individuals or employers to buy separate coverage, they must use entirely non-federal money, meaning no tax credits or subsidized funds can touch that premium.
This legislation directly impacts individuals seeking gender transition procedures who rely on federal programs, whether through the VA, federal employment, or ACA subsidies. For these groups, access to care is severely restricted, forcing them to pay full price for treatments that may be medically necessary, or go without. The bill is clear that states or individuals can still pay for this coverage, but they must do so without using any federal matching funds, which makes it administratively complex for state-level programs like Medicaid to offer alternative coverage options. Essentially, if you need this care, the federal government is making sure that your tax dollars won't help you pay for it, significantly increasing the cost and complexity of accessing treatment.